The 36-month beta value for IMUX is at 1.50. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMUX is 92.59M, and currently, shorts hold a 4.59% of that float. The average trading volume for IMUX on June 12, 2025 was 1.36M shares.
IMUX) stock’s latest price update
The stock price of Immunic Inc (NASDAQ: IMUX) has dropped by -2.27 compared to previous close of 0.87. Despite this, the company has seen a gain of 10.01% in its stock price over the last five trading days. seekingalpha.com reported 2025-06-09 that Immunic, Inc.’s CALLIPER study showed vidofludimus calcium reduced disability progression by 30% in PPMS patients, despite modest MRI results, suggesting strong neuroprotective effects. IMUX stock’s significant drop appears to be an overreaction, given the positive disability progression data and clean safety profile. The company plans a Phase 3 trial focusing on confirmed disability progression, a key regulatory endpoint, to confirm these promising results.
IMUX’s Market Performance
Immunic Inc (IMUX) has seen a 10.01% rise in stock performance for the week, with a -14.10% decline in the past month and a -24.08% plunge in the past quarter. The volatility ratio for the week is 4.73%, and the volatility levels for the past 30 days are at 7.63% for IMUX. The simple moving average for the past 20 days is -0.14% for IMUX’s stock, with a -26.88% simple moving average for the past 200 days.
Analysts’ Opinion of IMUX
H.C. Wainwright, on the other hand, stated in their research note that they expect to see IMUX reach a price target of $10. The rating they have provided for IMUX stocks is “Buy” according to the report published on November 25th, 2024.
Leerink Partners gave a rating of “Outperform” to IMUX, setting the target price at $5 in the report published on September 09th of the previous year.
IMUX Trading at -11.00% from the 50-Day Moving Average
After a stumble in the market that brought IMUX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.70% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMUX starting from Tardio Jason, who purchase 12,512 shares at the price of $0.79 back on Jun 05 ’25. After this action, Tardio Jason now owns 12,512 shares of Immunic Inc, valued at $9,884 using the latest closing price.
Vitt Daniel, the CEO and Director of Immunic Inc, purchase 15,000 shares at $0.77 during a trade that took place back on Jun 04 ’25, which means that Vitt Daniel is holding 29,000 shares at $11,550 based on the most recent closing price.
Stock Fundamentals for IMUX
The total capital return value is set at 19.89. Equity return is now at value -246.26, with -154.64 for asset returns.
Based on Immunic Inc (IMUX), the company’s capital structure generated -0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -393.2.
Currently, EBITDA for the company is -100.37 million with net debt to EBITDA at 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.74.
Conclusion
In conclusion, Immunic Inc (IMUX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
